Avalo Therapeutics, INC 8-K filings

Avalo Therapeutics announced its second quarter 2026 financial results, detailing progress in its Phase 3 program for abdakibart and expansion with AVTX-010, supported by a robust cash reserve extending into 2029.

Avalo Therapeutics announces the advancement of AVTX-010, a long-acting anti-IL-1 antibody, with an IND submission planned for the first half of 2027.

Avalo Therapeutics executed a preferred stock exchange and amended executive employment agreements regarding change-in-control provisions.

Avalo Therapeutics held its 2026 annual meeting, with stockholders approving amendments to its Employee Stock Purchase Plan and ratifying the appointment of its independent auditor.

Avalo Therapeutics announced positive Phase 2 results for abdakibart in hidradenitis suppurativa and secured $431.3 million in financing, positioning it for Phase 3 trials.

Avalo Therapeutics announced positive topline results from its Phase 2 LOTUS trial for abdakibart in moderate to severe hidradenitis suppurativa, meeting primary endpoints and demonstrating a favorable safety profile.

Avalo Therapeutics announced an amendment to its merger agreement with AlmataBio, introducing a buyout option that significantly reduces potential future milestone payments.

Two Avalo Therapeutics board members, Dr. Jonathan Goldman and Mitchell Chan, will not seek re-election at the company's 2026 Annual Meeting of Stockholders.

Avalo Therapeutics announced its 2025 financial results and anticipates topline data from its Phase 2 LOTUS trial for abdakibart in Q2 2026.

Avalo Therapeutics, Inc. announced an estimated $98 million in cash, cash equivalents, and short-term investments as of December 31, 2025, providing a cash runway into 2028, alongside completed enrollment for its Phase 2 LOTUS trial in hidradenitis suppurativa.

Avalo Therapeutics announces completion of enrollment for its Phase 2 LOTUS trial of AVTX-009 for Hidradenitis Suppurativa, with topline data expected Q2 2026.

Avalo Therapeutics announced the completion of enrollment for its Phase 2 LOTUS trial for AVTX-009, with topline data expected mid-2026, and reported a cash runway into 2028.

Avalo Therapeutics announced the completion of enrollment for its Phase 2 LOTUS trial of AVTX-009 for hidradenitis suppurativa, exceeding its target patient count.

Avalo Therapeutics, Inc. (AVTX) released an updated investor presentation showcasing its lead compound AVTX-009 for hidradenitis suppurativa and a cash runway into 2028.

Avalo Therapeutics announced the appointment of Taylor Boyd as Chief Business Officer and Ashley Ivanowicz as Senior Vice President, Human Resources, strengthening its leadership team for a transformational period.

Avalo Therapeutics strengthens its board with the appointment of Kevin Lind, a seasoned biotech executive known for successful company exits and capital raises, while Dr. June Almenoff resigns.

Avalo Therapeutics announced its second quarter 2025 financial results, highlighting progress in its Phase 2 LOTUS trial for hidradenitis suppurativa and a strong cash position.

Avalo Therapeutics, Inc. (AVTX) released an updated investor presentation highlighting its lead compound AVTX-009 for hidradenitis suppurativa and its financial runway into 2028.

Avalo Therapeutics, Inc. announced the appointment of Dr. Rita Jain to its Board of Directors and the approval of an amended non-employee director compensation plan, effective June 17, 2025.

Avalo Therapeutics, Inc. announced that all proposals, including the election of eight directors, the advisory approval of executive compensation, and the ratification of Ernst & Young LLP as its independent auditor, were approved by shareholders at its 2025 Annual Meeting.

Avalo Therapeutics, Inc. has entered into a new sales agreement with TD Securities (USA) LLC to offer and sell up to $75.0 million of its common stock through an At-The-Market offering, replacing its prior $50.0 million facility with Oppenheimer & Co. Inc.

Avalo Therapeutics, Inc. (AVTX) has released an updated investor presentation highlighting its lead compound AVTX-009 for hidradenitis suppurativa (HS) and projecting a significant market opportunity with a cash runway into at least 2027.

Avalo Therapeutics announced its Q1 2025 financial results, highlighting progress in the Phase 2 LOTUS trial for AVTX-009 and a cash runway into 2027.

Avalo Therapeutics presents an updated investor presentation focusing on AVTX-009, a potential best-in-disease treatment for hidradenitis suppurativa (HS), with topline Phase 2 LOTUS trial data expected in 2026 and a cash runway into at least 2027.

Avalo Therapeutics appoints Michael Heffernan as Chairman of the Board, succeeding Dr. Garry Neil, effective immediately.

Avalo Therapeutics announces its 2024 financial results, highlights progress on its AVTX-009 program, and appoints a new Chief Strategy Officer.

Avalo Therapeutics is advancing AVTX-009, a highly specific IL-1 inhibitor, with the potential to be a best-in-disease treatment for hidradenitis suppurativa (HS), a market expected to exceed $10 billion by 2035.

Avalo Therapeutics has appointed Jennifer Riley as Chief Strategy Officer, effective January 1, 2025, to oversee corporate strategy and commercial planning.

Avalo Therapeutics presents an updated investor presentation focusing on AVTX-009, a potential best-in-disease treatment for hidradenitis suppurativa, with a phase 2 trial underway and topline data expected in 2026.

Avalo Therapeutics has received $69.4 million in gross proceeds from the full exercise of warrants issued in a March 2024 private placement, extending their cash runway into at least 2027.